ROXANA ROPOS: Open Payments
NPI 1437725595 · GRAPEVINE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,831 in 57 payments from 10 companies in 2025. Trend: 2023 $189 · 2024 $700 · 2025 $1,831
Food & beverage: $1,831
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 9 | $401 |
| Novartis Pharmaceuticals Corporation | 10 | $364 |
| Janssen Biotech, Inc. | 10 | $359 |
| ABBVIE INC. | 10 | $230 |
| Radius Health, Inc. | 3 | $160 |
| Amgen Inc. | 8 | $142 |
| GlaxoSmithKline, LLC. | 3 | $67 |
| GENZYME CORPORATION | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| Fresenius Kabi USA, LLC | 1 | $25 |
Products named: Bimzelx, TREMFYA, COSENTYX, Tymlos, SKYRIZI, RINVOQ, BENLYSTA, TAVNEOS.
Industry payments across TX — which companies pay providers there.
